جدول الترويج Greenwich LifeSciences, Inc.
الجدول الزمني المتقدم
رسم بياني بسيط
عن الشركة Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.| IPO date | 2020-09-25 |
|---|---|
| ISIN | US3968791083 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://greenwichlifesciences.com |
| Цена ао | 10.63 |
| تغير السعر يوميا: | -0% (10.71) |
|---|---|
| تغير السعر في الأسبوع: | -3.6% (11.11) |
| تغير السعر شهريا: | -8.93% (11.76) |
| تغير السعر خلال 3 أشهر: | -6.87% (11.5) |
| تغير السعر على مدى ستة أشهر: | -25.47% (14.37) |
| تغير السعر سنويا: | -46.29% (19.94) |
| تغير السعر على مدى 3 سنوات: | -50.6% (21.68) |
| تغير الأسعار منذ بداية العام: | -13.56% (12.39) |
|
|
الاستهانة
|
كفاءة
|
|||||||||||||||||||||||||||||||||||||
توزيعات الأرباح
|
واجب
|
دافع النمو
|
|||||||||||||||||||||||||||||||||||||
| المؤسسات | مقدار | يشارك, % |
|---|---|---|
| Vanguard Group Inc | 221682 | 1.73 |
| Blackrock Inc. | 57148 | 0.44 |
| Ameriprise Financial, Inc. | 53647 | 0.42 |
| Geode Capital Management, LLC | 46816 | 0.36 |
| Renaissance Technologies, LLC | 36600 | 0.28 |
| Northern Trust Corporation | 20983 | 0.16 |
| 683 Capital Management LLC | 19604 | 0.15 |
| Qube Research & Technologies Ltd | 14714 | 0.11 |
| JANE STREET GROUP, LLC | 14005 | 0.11 |
| State Street Corporation | 13002 | 0.1 |
| ETF | يشارك, % | الربحية لهذا العام, % | توزيعات الأرباح, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.02306 | 17.09 | 1.54048 |
| Vanguard Russell 2000 Growth ETF | 0.01 | 23.05 | 0.60264 |
iShares Russell 2000 Growth ETF
|
0.00627 | 38.04 | 0.6026 |
ProShares UltraPro Russell2000
|
0.00192 | 89.82 | 1.47873 |
| ProShares Hedge Replication ETF | 0.0005 | 5.92 | 1.47892 |
| Vanguard Russell 2000 ETF | 0 | 17.16 | 1.48801 |
| Vanguard Russell 3000 ETF | 0 | 31.87 | 1.43817 |
| 0.01 | 31.85 | 1.23 |
| مشرف | مسمى وظيفي | قسط | سنة الميلاد |
|---|---|---|---|
| Mr. Snehal S. Patel | CEO, CFO & Director | 1.09M | 1964 (61 سنة) |
| Mr. Eric Rothe | Founder & Independent Director | 65.64k | 1976 (49 سنين) |
| Dr. Frank Joseph Daugherty M.D. | Chief Medical Officer & Director | N/A | 1951 (74 سنة) |
| Dr. Jaye L. Thompson Ph.D. | Vice President Clinical & Regulatory Affairs | N/A | 1966 (59 سنين) |
| Dr. Christine T. Fischette Ph.D. | VP of Business Development | N/A | 1951 (74 سنة) |
عنوان: United States, Stafford. TX, Building 14 - مفتوحة في خرائط جوجل, فتح خرائط ياندكس
موقع إلكتروني: https://greenwichlifesciences.com
موقع إلكتروني: https://greenwichlifesciences.com
